SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

AJANTA PHARMA

BSE: 532331 28 Jun 2025
Healthcare
₹ 2567.8
Ajanta Pharma Ltd. specializes in Pharmaceuticals within the Healthcare sector.

AJANTA PHARMA - Share Price & Details

Market Cap
₹31,487
High /Low
3,486 / 2,022
Stock P/E
34.4
Book Value
₹303.0
Dividend Yield
1.43
ROCE
32.4
ROE
₹24.9
Face Value
2.0
PEG Ratio
2.41
EVEBITDA
₹23.3
Debt
47.4
CMP / FCF
44.9
Debt to equity
₹0.01
NP Ann
920
High price all time
3,486
Piotroski score
₹6.0
Graham Number
709.0
No. Eq. Shares
12.5
Net CF
₹47.3
Net profit
920
Price to book value
8.31
Interest Coverage
₹58.1
Low price all time
4.03
Industry PE
32.7
Reserves
₹3,765
Free Cash Flow
₹840

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
AJANTA PHARMA LTD.11885.22252.611704.11831,48734.4
Global Health Limited8285.34934.128028.683.483039158.6
Aster DM Healthcare Limited6089.9610.75738.61.222895372.6

Peer Comparison Chart


About AJANTA PHARMA

Ajanta Pharma Ltd., with Security Code 532331, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Stock market update: Nifty Pharma index advances 0.08%

(05 Jun 2025)
NEW DELHI: The Nifty Pharma index closed on a positive note on Wednesday. ADVERTISEMENT. Shares of Gland Pharma Ltd.(up 2.3 per cent),...
Read more →

Stock market update: Nifty Pharma index falls 0.68%

(05 Jun 2025)
NEW DELHI: The Nifty Pharma index closed on a negative note on Friday. Shares of Glenmark Pharmaceuticals Ltd.(up 3.61 per cent), Gland Pharma Ltd.(up 0.66...
Read more →

Ajanta Pharma elevates Prafull Bhandari to Senior Vice President - PPIC

(24 May 2025)
Mumbai: Ajanta Pharma has promoted Prafull Bhandari to the position of Senior Vice President Production Planning & Inventory Control (PPIC).
Read more →

Stock market update: Nifty Pharma index advances 1.22%

(19 May 2025)
NEW DELHI: The Nifty Pharma index closed on a positive note on Tuesday. Shares of Ajanta Pharma Ltd.(up 4.45 per cent), Granules India...
Read more →

Ajanta Pharma Q4 Review: Revenue Inline But Margins Contract- Systematix Maintains Buy, Cuts Target Price

(03 May 2025)
Ajanta Pharma Ltd.'s Q4 FY25 revenue (Rs 11704 million) was in-line with expectations (up 11% YoY and 2% QoQ), but Ebitda came in lower...
Read more →

Buy Ajanta Pharma; Target Price Revised

(03 May 2025)
In its latest research report dated May 2, 2025, Choice Equity Broking has maintained a bullish stance on Ajanta Pharma Ltd., recommending a...
Read more →